Cilt & Saç

Synthetic copper-binding tripeptide targeting dermal papilla cells and hair follicles. Stimulates hair follicle elongation, promotes cell proliferation, increases VEGF production, and inhibits TGF-β1. Supports skin regeneration through fibroblast activation and collagen synthesis.

Clascoterone (cortexolone 17-alpha-propionate) is a first-in-class topical androgen receptor inhibitor developed by Cassiopea SpA. In August 2020, the FDA approved Winlevi (clascoterone cream 1%) for the treatment of acne vulgaris in patients aged 12 and older, making it the first new mechanism of action for acne treatment in nearly four decades and the first topical anti-androgen approved for acne in the United States. Clascoterone is also under development as Breezula (clascoterone solution 7.5%) for androgenetic alopecia, where it has completed Phase 3 clinical trials. The compound works by competitively inhibiting androgen receptor activation at the site of application -- the sebaceous gland for acne and the hair follicle for androgenetic alopecia -- without producing the systemic anti-androgenic effects associated with oral anti-androgens such as spironolactone or cyproterone acetate. Its steroidal structure allows it to fit precisely into the androgen receptor binding pocket, and its rapid local metabolism to cortexolone (an inactive metabolite) limits systemic exposure. This pharmacological profile makes clascoterone suitable for use in both men and women, unlike systemic anti-androgens which carry risks of feminization in male patients.

Naturally occurring copper tripeptide found in human plasma, saliva, and urine. GHK-Cu affects 31.2% of human genes and declines significantly with age—from ~200 ng/ml at age 20 to ~80 ng/ml at age 60. Known for exceptional skin regeneration, wound healing, and anti-aging properties.

Combination featuring BPC-157, TB-500, and GHK-Cu marketed for skin rejuvenation and anti-aging. Individual components have research support, but combination protocols require careful dosing to avoid exceeding therapeutic ranges.

Synthetic analog of α-MSH that selectively targets MC1 receptors for melanin stimulation. FDA-approved as SCENESSE implant for erythropoietic protoporphyria (EPP). Research-grade injectable form enables flexible dosing versus the implant version.

Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors throughout the body. MC1R activation triggers melanin production for tanning, while MC4R affects sexual arousal and appetite control.

Synthetic octapeptide functioning as topical Botox alternative, targeting dynamic facial wrinkles through SNARE complex modulation. Up to 63% wrinkle depth reduction demonstrated clinically.

Tretinoin is the gold standard topical retinoid for skin aging and acne, FDA-approved since 1971 for acne vulgaris and later for the treatment of photoaging (fine wrinkles, mottled hyperpigmentation, roughness). As the acid form of vitamin A, it is the most extensively studied topical anti-aging compound in dermatology, backed by decades of clinical evidence. Tretinoin accelerates epidermal cell turnover, stimulates collagen synthesis in the dermis, and improves the overall architecture of photodamaged skin. It has become a cornerstone of the biohacking and skincare optimization community due to its proven ability to reduce fine lines, even out skin tone, and improve skin texture with consistent long-term use.